Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I trial using practical measures (n = 286). Spleen length alone was insufficient for identifying all patients who received clinical benefit, emphasizing the importance of using multiple myelofibrosis assessment methods in the community setting. Background The phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I and COMFORT-II trials in patients with intermediate-2 or high-risk myelofibrosis (MF) showed that ruxolitinib was superior to placebo and best available therapy, respectively, for improvements in spleen volume, MF-related symptoms, and overall survival (OS). However, patients managed in community settings might not have access to the methods used in the COMFORT trials. In this exploratory analysis we summarize efficacy findings of COMFORT-I using practical, community-oriented measures of patient outcomes. Patients and Methods In this post hoc analysis of data from COMFORT-I we evaluated changes from baseline to week 12 in spleen size (palpable length and volume), patient-reported outcomes (Patient Global Impression of Change; Myelofibrosis Symptom Assessment Form; Patient-Reported Outcomes Measurement System Fatigue Scale), body weight, and serum albumin levels in 5 subgroups of ruxolitinib-treated patients on the basis of week 12 spleen length changes from baseline: (1-4) ≥ 50%, 25% to < 50%, 10% to < 25%, or < 10% reduction; and (5) worsening. OS was evaluated in ruxolitinib-treated patients with week 12 spleen length reductions from baseline ≥ 50%, 25% to < 50%, or < 25% (including worsening). Results In all spleen length subgroups, including patients with worsening spleen length at week 12, ruxolitinib (n = 150) was associated with improvements in spleen volume, patient-reported symptom burden, body weight, and serum albumin levels. Greater reductions in spleen length were associated with prolonged OS. Conclusion A variety of assessment methods beyond palpable spleen length that are easily accessible in the community setting might be useful in evaluating the clinical benefit of ruxolitinib over time in patients with MF.

Original languageEnglish (US)
Pages (from-to)479-487
Number of pages9
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number8
DOIs
StatePublished - Aug 2017

    Fingerprint

Keywords

  • Community hospitals
  • Janus kinases
  • Myelofibrosis
  • Myeloproliferative disorders
  • Splenomegaly

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this